SG188424A1 - Ingredients derived from sphaeranthus indicus - Google Patents
Ingredients derived from sphaeranthus indicus Download PDFInfo
- Publication number
- SG188424A1 SG188424A1 SG2013016597A SG2013016597A SG188424A1 SG 188424 A1 SG188424 A1 SG 188424A1 SG 2013016597 A SG2013016597 A SG 2013016597A SG 2013016597 A SG2013016597 A SG 2013016597A SG 188424 A1 SG188424 A1 SG 188424A1
- Authority
- SG
- Singapore
- Prior art keywords
- energy
- extract
- sphaeranthus indicus
- mammal
- derived
- Prior art date
Links
- 239000004615 ingredient Substances 0.000 title claims abstract description 62
- 244000085223 Sphaeranthus indicus Species 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 claims abstract description 100
- 241001465754 Metazoa Species 0.000 claims abstract description 52
- 230000003340 mental effect Effects 0.000 claims abstract description 47
- 230000036626 alertness Effects 0.000 claims abstract description 44
- 230000002708 enhancing effect Effects 0.000 claims abstract description 31
- 241000124008 Mammalia Species 0.000 claims abstract description 26
- 238000012423 maintenance Methods 0.000 claims abstract description 26
- -1 frullanolide/eudesmanoid sesquiterpene compound Chemical class 0.000 claims abstract description 24
- 230000007103 stamina Effects 0.000 claims abstract description 18
- 230000036541 health Effects 0.000 claims abstract description 16
- 230000037081 physical activity Effects 0.000 claims abstract description 16
- 230000003840 blood vessel health Effects 0.000 claims abstract description 14
- 239000003623 enhancer Substances 0.000 claims abstract description 14
- 230000004630 mental health Effects 0.000 claims abstract description 13
- 235000013361 beverage Nutrition 0.000 claims abstract description 9
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 8
- 235000012041 food component Nutrition 0.000 claims abstract description 8
- 239000005417 food ingredient Substances 0.000 claims abstract description 7
- 235000011888 snacks Nutrition 0.000 claims abstract description 6
- 235000015897 energy drink Nutrition 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims description 75
- XMPDAVDYIOMTLX-UHFFFAOYSA-N 7-hydroxy eudesm-4-en-6,12-olide Natural products C1CC2(C)CCCC(C)=C2C2OC(=O)C(=C)C21O XMPDAVDYIOMTLX-UHFFFAOYSA-N 0.000 claims description 28
- 240000006053 Garcinia mangostana Species 0.000 claims description 25
- 235000017048 Garcinia mangostana Nutrition 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 22
- GNRIZKKCNOBBMO-UHFFFAOYSA-N alpha-mangostin Chemical compound OC1=C(CC=C(C)C)C(O)=C2C(=O)C3=C(CC=C(C)C)C(OC)=C(O)C=C3OC2=C1 GNRIZKKCNOBBMO-UHFFFAOYSA-N 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- 229940088594 vitamin Drugs 0.000 claims description 13
- 229930003231 vitamin Natural products 0.000 claims description 13
- 235000013343 vitamin Nutrition 0.000 claims description 13
- 239000011782 vitamin Substances 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229940024606 amino acid Drugs 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 241000283690 Bos taurus Species 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 5
- 235000013399 edible fruits Nutrition 0.000 claims description 5
- 241001184073 Basilicum Species 0.000 claims description 4
- 244000194101 Ginkgo biloba Species 0.000 claims description 4
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 4
- 240000003444 Paullinia cupana Species 0.000 claims description 4
- 235000000556 Paullinia cupana Nutrition 0.000 claims description 4
- 241001165494 Rhodiola Species 0.000 claims description 4
- 241001521901 Tribulus lanuginosus Species 0.000 claims description 4
- 244000273928 Zingiber officinale Species 0.000 claims description 4
- 229910052762 osmium Inorganic materials 0.000 claims description 4
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 229960003080 taurine Drugs 0.000 claims description 4
- PJPHIAMRKUNVSU-NJZAAPMLSA-N Frullanolide Chemical compound C1C[C@@]2(C)CCCC(C)=C2[C@@H]2OC(=O)C(=C)[C@@H]21 PJPHIAMRKUNVSU-NJZAAPMLSA-N 0.000 claims description 3
- PJPHIAMRKUNVSU-UHFFFAOYSA-N gamma-cyclocostunolide Natural products C1CC2(C)CCCC(C)=C2C2OC(=O)C(=C)C21 PJPHIAMRKUNVSU-UHFFFAOYSA-N 0.000 claims description 3
- 229930004725 sesquiterpene Natural products 0.000 claims description 3
- LKKDASYGWYYFIK-JURCDPSOSA-N (+)-4-epi-cryptomeridiol Chemical compound C1CC[C@](C)(O)[C@H]2C[C@@H](C(C)(O)C)CC[C@@]21C LKKDASYGWYYFIK-JURCDPSOSA-N 0.000 claims description 2
- LKKDASYGWYYFIK-UHFFFAOYSA-N (-)-cryptomeridiol Natural products C1CCC(C)(O)C2CC(C(C)(O)C)CCC21C LKKDASYGWYYFIK-UHFFFAOYSA-N 0.000 claims description 2
- XJIHHYMEBKDQFZ-RQXOCINCSA-N (3r,3ar,5ar,8r,9bs)-3a-hydroxy-3,5a,9-trimethyl-8-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6,7,8,9b-hexahydro-3h-benzo[g][1]benzofuran-2-one Chemical compound O([C@H]1C(C)=C2[C@@H]3OC(=O)[C@@H]([C@@]3(CC[C@@]2(C)CC1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJIHHYMEBKDQFZ-RQXOCINCSA-N 0.000 claims description 2
- PYDYAPFBFDTVMM-UHFFFAOYSA-N Cryptomeridiol Natural products C1CCC(O)C2CC(C(C)(O)C)CCC21C PYDYAPFBFDTVMM-UHFFFAOYSA-N 0.000 claims description 2
- XJIHHYMEBKDQFZ-LBYJFOIVSA-N Sphaeranthanolide Natural products O([C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)=C2[C@](C)(CC1)CC[C@@]1(O)[C@H](C)C(=O)O[C@@H]21 XJIHHYMEBKDQFZ-LBYJFOIVSA-N 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000012676 herbal extract Substances 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- OQYBLUDOOFOBPO-UHFFFAOYSA-N Asterolide Natural products C1C2C(=C)CCCC2(C)CC2C1=C(C)C(=O)O2 OQYBLUDOOFOBPO-UHFFFAOYSA-N 0.000 claims 1
- CCOGMNXJHQYPKW-UHFFFAOYSA-N Desacetyldihydro-beta-cycloisopyrethrosin Natural products CC1C2C(O)CC3(C)C(O)CCC(=C)C3C2OC1=O CCOGMNXJHQYPKW-UHFFFAOYSA-N 0.000 claims 1
- 229930000731 eudesmanolide Natural products 0.000 claims 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 14
- 230000009182 swimming Effects 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 230000036314 physical performance Effects 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 235000003599 food sweetener Nutrition 0.000 description 14
- 239000003765 sweetening agent Substances 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000036997 mental performance Effects 0.000 description 12
- 239000000401 methanolic extract Substances 0.000 description 12
- 230000000284 resting effect Effects 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 206010016256 fatigue Diseases 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000013589 supplement Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000469 ethanolic extract Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000010162 Tukey test Methods 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 150000005846 sugar alcohols Chemical class 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229910002012 Aerosil® Inorganic materials 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 239000000619 acesulfame-K Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 210000000107 myocyte Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000017807 phytochemicals Nutrition 0.000 description 3
- 229930000223 plant secondary metabolite Natural products 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- QTDMGAWIBXJNRR-UHFFFAOYSA-N Mangostin Natural products CC(=CCc1c(O)cc2Oc3cc(C)c(O)c(CC=C(C)C)c3C(=O)c2c1O)C QTDMGAWIBXJNRR-UHFFFAOYSA-N 0.000 description 2
- 208000019914 Mental Fatigue Diseases 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 241001622452 Sphaeranthus Species 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000009194 climbing Effects 0.000 description 2
- 235000016213 coffee Nutrition 0.000 description 2
- 235000013353 coffee beverage Nutrition 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000011869 dried fruits Nutrition 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000009945 mood elevation Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- TZBGSHAFWLGWBO-ABLWVSNPSA-N (2s)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pteridin-6-yl)methylamino]benzoyl]amino]-5-methoxy-5-oxopentanoic acid Chemical compound C1=CC(C(=O)N[C@@H](CCC(=O)OC)C(O)=O)=CC=C1NCC1NC(C(=O)NC(N)=N2)=C2NC1 TZBGSHAFWLGWBO-ABLWVSNPSA-N 0.000 description 1
- KNIZBZYMVRWQKN-DMTCNVIQSA-N (3s)-3-amino-4-[[(2r)-1-amino-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical class NC(=O)[C@@H](C)NC(=O)[C@@H](N)CC(O)=O KNIZBZYMVRWQKN-DMTCNVIQSA-N 0.000 description 1
- VMQCQYRHANDJBP-IUYQGCFVSA-N (3s)-3-amino-4-[[(2r)-1-amino-3-hydroxy-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical class OC(=O)C[C@H](N)C(=O)N[C@H](CO)C(N)=O VMQCQYRHANDJBP-IUYQGCFVSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Chemical group 0.000 description 1
- YZQCXOFQZKCETR-UWVGGRQHSA-N Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YZQCXOFQZKCETR-UWVGGRQHSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Chemical group 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 102100027256 Melanoma-associated antigen H1 Human genes 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 235000006089 Phaseolus angularis Nutrition 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 244000185386 Thladiantha grosvenorii Species 0.000 description 1
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 description 1
- 240000007098 Vigna angularis Species 0.000 description 1
- 235000010711 Vigna angularis Nutrition 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003270 Vitamin B Chemical group 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000008272 agar Chemical group 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000390 anti-adipogenic effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000008207 calcium folinate Nutrition 0.000 description 1
- 239000011687 calcium folinate Substances 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Chemical group 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical group NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000008370 chocolate flavor Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 108010038764 cytoplasmic linker protein 170 Proteins 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004300 dark adaptation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940022862 garcinia mangostana fruit rind extract Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Chemical group 0.000 description 1
- 229920000159 gelatin Chemical group 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930189775 mogroside Natural products 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000001814 pectin Chemical group 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Chemical group 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000037074 physically active Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229940071207 sesquicarbonate Drugs 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960004860 thiamine mononitrate Drugs 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 235000019191 thiamine mononitrate Nutrition 0.000 description 1
- 239000011748 thiamine mononitrate Substances 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 239000008371 vanilla flavor Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical group [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses herbal ingredients derived from Sphaeranthus indicus standardized to at least one frullanolide/eudesmanoid sesquiterpene compound and their compositions as natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a mammal. The invention further includes the use of ingredients and compositions for food ingredient formulations such as dietary supplement, food ingredient, beverage, snack or energy drink containing the above said herbal ingredient(s) for enhancing physical activity, physical fitness, mental alertness, enhancing energy levels, stamina levels, circulatory health, blood vessel health and for better mental health in warm blooded animal.
Description
“SPHAERANTHUS INDICUS DERIVED INGREDIENTS AND THEIR
COMPOSITIONS FOR ENHANCING PHYSICAL PERFORMANCE AND
ENERGY LEVELS”
The invention discloses a herbal ingredient selected from extracts and fractions standardized to at least one frullanolide/eudesmanoid sesquiterpene compound(s) derived from Sphaeranthus indicus or their composition(s) as natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a mammal.
The invention further relates to food ingredient formulations such as beverages, dietary ingredient formulation, snacks and energy drinks containing the above said herbal ingredient or its composition(s) for onset and steady maintenance of energy and mental alertness such as enhancing physical activity, physical fitness, mental alertness, energy levels, stamina levels, circulatory health, blood vessel health or for better physical and mental health. :
Physical activity, such as exercise, particularly in the heat, places a demand on the body's carbohydrate stores, such as muscle glycogen, liver glycogen, and plasma glucose. Loss of water, redistribution and loss of electrolytes, and the depletion of endogenous carbohydrate reserves are primary causes of fatigue/tiredness that impairs one's work capacity. To maintain the body's physical capabilities, it is essential that water, electrolytes, carbohydrate, and other nutrients be provided in a timely and appropriate manner. Fluid replacement during physical activity has been shown to be effective in preventing dehydration and hyperthermia.
The basic force and condition behind all activities of human life is the presence of energy.
Energy is the vital principle needed to sustain life and it is required for every aspect of existence - every act uses energy - thinking, feeling, walking, eating, drinking, dreaming, breathing etc. Energy is felt and experienced upon its expenditure. The energy we experience immediately after eating (such as sweets), or the hype we get following the consumption of coffee is from the expenditure of energy from body's energy reserves, not through its accumulation. Age, fatigue and stress make people feel deficient in energy.
This drag in energy very often compromises body's mental alertness. Addressing body's energy demands properly, will increase one’s efficiency at work place and in personal management.
Dietary supplements are used by physically active people or weak people to increase their physical performance, physical fitness, improve their health, or reduce the potentially negative consequences of physical activity such as injury and chronic fatigue, or suppressed immune function.
Many energy beverages, supplements and food ingredient formulations are presently available in the market. However, these are fully loaded with disaccharides, carbohydrate complexes, proteins, amino acids and vitamins along with numerous other agents. Many of these formulations act too quickly to give rise instant energy and not maintained over sustained period of time. Besides, these formulations tend to increase the blood glucose levels sharply and this is followed by their rapid depletion. This might some times lead to complications. Natural supplements, which improve the feeling of being energetic, general agility, endurance and mental alertness are thus in great demand. Studies are in process in many research groups across the globe to develop a superior product to address the above requirements.
Therefore, the present invention addresses the existing need in the art by providing an ingredient(s) or composition(s) that provides energy and/or mental alertness. Thus, the present invention provides ingredient(s) and/or composition(s) capable of increasing energy levels for an extended period of time in a mammal to enhance both energy levels and mental alertness and thus solves these needs.
In a major embodiment, the invention discloses a herbal ingredient selected from extracts and fractions standardized to at least one frullanolide/eudesmanoid sesquiterpene compound(s) derived from Sphaeranthus indicus or their composition(s) for onset and steady maintenance of energy and mental alertness. The sphaeranthus derived ingredient and its compositions are useful for enhancing physical activity, physical fitness, mental alertness, energy levels, stamina levels, circulatory health, blood vessel health or for better physical and mental health in a mammal.
In another embodiment, the invention relates to the preparation of dietary supplements, food ingredient formulations such as beverages, snacks and energy drinks containing the above said ingredient(s) or its composition(s) for onset and steady maintenance of energy and mental alertness. The formulation is useful for enhancing physical activity, physical fitness, mental alertness, energy levels, stamina levels, circulatory health, blood vessel health or for better physical and mental health in a mammal. .
In a further embodiment, the extracts or fractions are standardized to 7- hydroxyfrullanolide, its analogs or their compositions for onset and steady maintenance of energy; mental alertness and for enhancing physical activity, physical fitness, mental alertness, energy levels, stamina levels, circulatory health, blood vessel health or for better mental health in warm blooded animals in need thereof,
In yet another embodiment, the invention provides compositions described above comprise at least one herbal ingredient selected from extract or fraction standardized to at least one frullanolide/eudesmanoid sesquiterpene compound(s) derived from
Sphaeranthus indicus in combination with at least one ingredient selected from extract(s), fraction(s), active compound(s), phytochemical(s), derived from plants), animal(s) or microorganisms with proven therapeutic health benefits; pharmaceutically or dietetically acceptable agents, active ingredients, vitamins, amino acids and minerals.
In still another embodiment, one or more herbal ingredients derived from Sphaeranthus indicus or their compositions are useful for onset and steady maintenance of energy; mental alertness and for enhancing physical activity, physical fitness, mental alertness, energy levels, stamina levels, circulatory health, blood vessel health or for better mental health in warm blooded animals in need thereof.
In another embodiment, the invention provides a method of increasing natural energy to provide an onset and steady maintenance of energy and mental alertness in a mammal, wherein the method comprises supplementing or treating the said mammal with at least one herbal ingredient selected from the extracts, fractions, compounds; extracts or fractions standardized to active compounds derived from Sphaeranthus indicus or their compositions.
Figure I: Figure shows Energy endurance capacity of L112508 on swimming parameters.
The bars represent resting time, moving slow time and moving fast times in seconds.
Values are expressed as Mean + S.E.M, n=6. * p<0.05 and ** p<0.01 as compared to
Control (ANOVA followed by Tukey’s test)
Figure II: Figure shows Percentage of energy endurance capacity of L112508. The bars represent percentage resting time, moving slow time and moving fast times in seconds.
Figure III: Figure shows Energy endurance capacity-Average distance travelled in mm.
The bars represent average travelled by the control group and treatment group of animals supplemented with 100 mg/kg or 250 mg/kg body weight. Values are expressed as Mean + S.E.M, n=6. ** p<0.01 as compared to Control (ANOVA followed by Tukey’s test.
Figure IV: Figure shows Energy Endurance capacity. The bars represent Average velocity exhibited by the control group and treatment group (100 mg/kg or 250 mg/kg body weight) of animals. Values are expressed as Mean + S.E.M, n=6. * p<0.05 as compared to Control (ANOVA followed by Tukey’s test).
For the purpose of this invention, the phrase ‘herbal ingredient” OR ‘herbal ingredients’
OR ‘said herbal ingredients’ used in the specification and claims of the present invention refer to the extract(s), fraction(s); extract(s) or fraction(s) standardized to at least one frullanolide/eudesmanoid sesquiterpene compound(s) derived from Sphaeranthus indicus or their composition(s). The phrase ‘herbal ingredient’ OR ‘herbal ingredients’ is used interchangeably through out the specification and the same may be appreciated as such by the person skilled in the art.
The word ‘composition’ OR ‘compositions’ OR ‘mixture’ OR ‘mixtures’ determine the combination of one or more ingredients selected from extract(s), fraction(s) or compound(s) derived from Sphaeranthus indicus or other biologically active ingredients.
The phrase ‘biologically active ingredient’ or ‘biologically active ingredients’ refers to other component(s) used for making compositions and selected from extract(s), fraction(s), active compound(s), phytochemical(s); powder(s) derived from plant(s), animal(s) or microorganisms with proven therapeutic health benefits; pharmaceutically or dietetically acceptable active ingredients, vitamins, amino acids or minerals.
The phrase ‘weak people’ means those individuals who may or may not be suffering from a disease and the weakness can be of physical or mental.
The word ‘subject’ OR ‘subjects’ means warm blooded animals, cold blooded animals, birds, horses, human beings or mammals of any sex.
The inventors during their search for new anti-obese supplements have screened a large number of plant extracts for anti-adipogenesis activity using an in vitro assay in 3T3-L1 pre-adipocyte cells and found that extracts of Sphaeranthus indicus showed potent anti- adipogenic activity. Subsequent studies have shown that Sphaeranthus indicus can potently ameliorate a wide range of metabolic protein markers directly related to obesity, diabetes, cardiovascular diseases and other metabolic disorders. The anti-obese efficacy of Sphaeranthus indicus was confirmed in an in vivo study in diet induced obesity and diet induced metabolic syndrome models of Sprague Dawley rats. The details of above experiments and the study results are described in inventor's previous Indian patent application and the corresponding PCT application 224/CHE/2009 filed 2™ February, 2009; PCT/IN2010/000053 filed 1% February, 2010.
In the present invention, a study was conducted using Sphaeranthus indicus extract standardized to 5% 7-hydroxyfrullanolide (LI12508) and a composition (LI12507F) containing Sphaeranthus indicus extract standardized to 5% 7-hydroxyfrullanolide in combination with Garcinia mangostana extract standardized to 10% a-mangostin (LI80018) to assess their efficacy as an anti-obese supplement in a double blind placebo controlled study in obese human subjects. ‘Sixty obese subjects (27.6 % male; 72.4 % female; ages 22-50 years) were included in a randomized, double-blind, placebo- controlled study of 56 days duration. The participants (BMI 30 to 40) were randomized into three groups; placebo, LI12508 group and LI112507F group. The participants received either 600 mg/day of LI112508 and 800 mg of LI12507F formulation in two divided doses or two identical placebo capsules and all of them remained on a calorie-controlled diet (2000 Calories/day) and 30 min walking for 8 weeks. Various parameters including, physical, anthropomorphic, biochemical and questionnaire based evaluation including quality of life. The S. indicus extract (LI12508) and its formulation LI12507F provided significant reduction in body weight in both the treatment groups and also indicated promise for their potential use in controlling serum triglyceride levels. In addition, both
LI12508 and LI12507F also showed unexpectedly improved quality of life and improved energy, exercise ability and endurance in subjects supplemented with the treatments when compared the placebo treated group. This includes increased mobility, increased walking speed, increased walking distance, lack of fatigue, feeling untired, feeling light and active.
Encouraged by this surprising result, the inventors evaluated the ability of the study products LI12508 and LI12507F to enhance the ATP levels in a cellular model. The intracellular ATP level in the cells treated cells with LI12508 and LI12507F were measured by luminescence based ATP detection assay system, ATPlite (PerkinElmer
Inc., Waltham, MA). Briefly, equal number of L6 Rat myocytes was plated in each well of a 96-well cell culture plate and cultured in DMEM supplemented with 10% FBS. The cells were treated with test samples (LI12508 and LI12507F) at 50 pg/mL. Intracellular
ATP level was quantitatively estimated from a standard curve plotted with luminescence units vs. known concentrations of ATP and the results compared with that obtained for the control treated sample as summarized in the table 1. Both the Sphaeranthus indicus extract standardized to 5% 7-HF (LI112508) and its composition (LI112507F) significantly increased the ATP levels in the rat myocyte cells, when compared to the control.
The Energy Endurance potential of LI12508 following oral administration was further evaluated in male and female Swiss albino mice. Swiss albino mice of 20 weeks old were selected and examined for health status and divided into three groups each consisting of 6 animals (3 males and 3 females). The control group animals were treated p.o with 0.5% of
CMC and treatment groups were treated once a day with the test compound LI12508 at 100 mg/kg or 250 mg/kg body weight for one week. On day 7, one hour after the treatment, the animals were tested for energy endurance with force swimming test using the SMART video tracking system (Panlab S.L.U). Resting time and its percentage, slow moving and its percentage, fast moving and its percentage, total path length of swimming and average velocity were analyzed using SMART video tracking software and the data is summarized in table 2.
Based on the results obtained, there was a dose dependent decrease in mean resting time in animals supplemented with 100 or 250 mg/kg of the test substance, LI12508. This mean reduction in resting time observed in treated groups is statistically significant when compared to control. In addition, the mean increase in slow swimming time, fast swimming time and average distance covered in both the treatment groups (100 mg/kg and 250 mg/kg) supplemented with LI12508 is also significant, when compared to control group as shown figures 1 to 3. Significant increase in average velocity was observed in animals treated with 250 mg/kg p.o as compared to control group as depicted in figure 4.
The increase in mean slow swimming time and mean fast swimming time reveals that the animals treated with LI112508 (100 mg/kg and 250 mg/kg) preferred to swim for a longer period of time instead of resting as observed in vehicle treated control animals. The increase in mean swimming velocity observed in 250 mg/kg LI12508 treated animals, further support the increase in mean distance covered by the animals in the shorter period of time as compared to other two groups. This indicates the animals treated with L112508 were very active and energetic during 15 minutes forced swimming period and could tend to swim either slow or fast most of the time rather than resting when compared to control group treated with 0.5% CMC. The longer distance covered at higher velocity and shorter resting times observed in L112508 treated animals indicate that L112508 improves energy and endurance. Hence, it is obvious that supplementation of Sphaeranthus indicus extract can increase the energy levels and endurance potential.
The forgoing demonstrates that Sphaeranthus indicus extract standardized to 5% 7- hydroxyfrullanolide (LI12508) and its composition in combination with Garcinia mangostana extract standardized to 10% a-mangostin (LI12507F) could be potent natural supplements to provide an onset, steady maintenance of energy, physical endurance and mental alertness in humans and animals.
Accordingly, in a major embodiment, the invention discloses a herbal ingredient selected from extracts and fractions standardized to at least one frullanolide/eudesmanoid sesquiterpene compound(s) derived from Sphaeranthus indicus or their composition(s) for onset and steady maintenance of energy and mental alertness. The sphaeranthus derived ingredients and its compositions are useful for enhancing physical activity, physical fitness, mental alertness, energy levels, stamina levels, circulatory health, blood vessel health or for better physical and mental health in a mammal.
In another embodiment the invention discloses the composition consisting of
Sphaeranthus indicus derived herbal ingredient in combination with at least one biologically active ingredient selected from extract of Garcinia mangostana fruit rind,
Osmium basilicum, Zingiber officinalis, Tribulus terrestris, vitamins, amino acids, taurine, an extract of Ginkgo biloba, Rhodiola and an extract of guarana, optionally in combination with an excipient, diluent or carrier as a natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof.
In another embodiment, the invention relates to at least one Sphaeranthus indicus derived herbal ingredient selected from the extracts and fractions standardized to 7- hydroxyfrullanolide or its analogs or mixtures thereof as a natural energy enhancer to provide an enhanced physical or mental performance, onset and steady maintenance of energy and mental alertness in a mammal.
In yet another embodiment, the invention relates to a composition comprising at least one herbal ingredient selected from extract or fraction standardized to at least one frullanolide/eudesmanoid sesquiterpene compound(s) derived from Sphaeranthus indicus or their composition(s) in combination with at least one ingredient selected from the extracts, fractions or compounds derived from Garcinia mangostana, further optionally containing at least one ingredient selected from excipient, diluent, vitamins or amino acids, as a natural energy enhancer for enhancing physical or mental performance, onset and steady maintenance of energy enhancing physical activity, physical fitness, mental alertness, energy levels, stamina levels, circulatory health, blood vessel health or for better mental health in a mammal.
In yet another embodiment, the invention provides a composition comprising at least one herbal ingredient selected from the extracts, fractions or compounds derived from
Sphaeranthus indicus in combination with at least one ingredient selected from the extracts, fractions or compounds derived from Garcinia mangostana, optionally containing at least ingredient selected from excipient, diluent, vitamins or amino acids, as a natural energy enhancer for enhancing physical or mental performance, onset and steady maintenance of energy and mental alertness in a mammal.
In another embodiment of the invention provides a composition comprising at least one herbal ingredient selected from the extracts or fractions standardized to at least one frullanolide/ eudesmanoid sesquiterpene compound such as 7-hydroxyfrullanolide (1) derived from Sphaeranthus indicus in combination with a Garcinia mangostana extract standardized to o-mangostin (2) or y-mangostin (3) and further optionally in combination with suitable excipients as a natural energy enhancer to provide an enhancing physical or mental performance, onset and steady maintenance of energy, mental alertness, for enhancing physical activity, physical fitness, energy levels, stamina levels, circulatory health, blood vessel health or for better mental health in a mammal.
Structures of 7-Hydroxyfrullanolide (1), a-mangostin (2) & y-mangostin (3) 0 OH =
OC
0 HO 0) OH 1 0 2. R= CH; 3. R=H
In still yet another embodiment of the invention provides a composition comprising at least one herbal ingredient selected from the extracts or fractions standardized to 5% 7-
hydroxyfrullanolide derived from Sphaeranthus indicus in combination with a Garcinia mangostana extract standardized to 10% a-mangostin and suitable excipients as a natural energy enhancer to provide an enhancing physical or mental performance, onset and steady maintenance of energy and mental alertness in a mammal.
In another important embodiment, examples of improved physical performance include increased stamina and improved speed, strength, power, endurance, flexibility, agility, balance, focus coordination, reaction time, fatigue recovery and also increase of sex stamina. Examples of improved mental performance include improved sharpness, attention span, mental alertness, cognitive functions, mood elevation, and recovery or reduction of mental fatigue (e.g., following a high-intensity physical exercise).
In another embodiment, the invention includes the preparation of dietary supplements, food ingredient formulations such as beverages, snacks and energy drinks containing the above said ingredient(s) or its composition(s) for enhancing physical activity, physical fitness, mental alertness, energy levels, stamina levels, circulatory health, blood vessel health or for better mental health in warm blooded animals in need thereof.
In yet another embodiment the invention provides at least one herbal ingredient selected from the extract(s), fraction(s), compound(s), extracts or fractions standardized to active compound(s)/7-hydroxyfrullanolide or its analogs derived from Sphaeranthus indicus and compositions as natural enhancers of energy instantly, physical performance in warm blooded animals in need thereof.
In another embodiment the extracts and/or fractions standardized to 7- hydroxyfrullanolide, its analogs or their compositions can be used for enhancing physical performance or energy levels in warm blooded animals.
In yet another embodiment the invention provides compositions comprising biologically active ingredients in combination with one or more components selected from extract(s), fraction(s), active compound(s), phytochemical(s); powder(s) derived from plant(s), animal(s) or microorganisms with proven therapeutic health benefits; pharmaceutically or dietetically acceptable agents, active ingredients, vitamins, amino acids or minerals.
In the other embodiment, the invention discloses composition containing Sphaeranthus indicus extract or fraction standardized to 7-hydroxyfrullanolide or its analogs in combination with at least one biologically active ingredient selected from an extract of
Garcinia mangostana, Osmium basilicum, Zingiber officinalis, Tribulus terrestris, vitamin
B, vitamin C, Vitamin E, taurine, an extract of ginkgo biloba, Rhodiola and an extract of guarana.
In another embodiment of the invention discloses the composition consisting of
Sphaeranthus indicus derived herbal ingredient in combination with at least one biologically active ingredient selected from extract of Garcinia mangostana fruit rind,
Osmium basilicum, Zingiber officinalis, Tribulus terrestris, vitamins, amino acids, taurine, an extract of Ginkgo biloba, Rhodiola and an extract of guarana, optionally in combination with an excipient, diluent or carrier as a natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof.
In another embodiment the invention discloses the compositions wherein the extract of
Garcinia mangostana fruit rind is standardized to o-mangostin or y-mangostin or both and optionally in combination with at least one excipient/diluent as a natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof.
In a further exemplary embodiment, the biologically active ingredients of the present invention for preparing the composition may further include one or more of the non- limiting components such as vitamins selected from B vitamins, including thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, cyanocobalamin, choline and/or folic acid, including the reduced forms of folic acid such as but not limited to folinic acid, calcium folinate and methyltetrahydrofolate. The B-complex vitamins are also water soluble vitamins that aid the breakdown of carbohydrates into glucose to provide energy for the body, the breakdown of fats and proteins to aid the normal functioning of the nervous system, and muscle tone in the stomach and intestinal tract. Particular forms of B vitamins in the composition may include d-Calcium pantothenate, niacinamide, pyridoxine hydrochloride, and thiamine mononitrate; or amino acids.
In another embodiment the Sphaeranthus indicus derived herbal ingredient selected from the extracts or fractions standardized to 7-hydroxyfrullanolide or its analogs or mixtures thereof and/or their composition(s) increases circulation, metabolism efficiency, regulates neurotransmitters and boosts oxygen levels in the brain. Benefits of enhanced circulation : in the brain include improved short and long term memory, increased reaction time and improved mental clarity.
In yet another embodiment the said herbal ingredients or their composition(s) are useful for enhancing energy levels, mental alertness, stamina levels, circulatory health and blood vessel health as well as for providing nutritional support. It can also be used as an energy booster for patients in need thereof, e.g., cancer patients or AIDS patients. Moreover, it is useful for enhancing athletic performance in both humans and animals, e.g., horses.
In another embodiment the said herbal ingredients and/or their composition(s) can be taken e.g. by performance athletes, those engaged in endurance and multi-discipline sports, aged and sick persons in order to increase mental and physical efficiency and to repress susceptibility to illnesses, such as cold, bacterial and viral infections, in a natural manner. The present ingredients and compositions may be formulated as a "fitness drink" that can be taken with breakfast or in the form of a concentrate from which such a drink can be regularly used.
In another embodiment 7-hydroxyfrullanolide or its analogs obtained naturally, synthesized or semi-synthesized can be useful for enhancing physical or mental performance.
In another embodiment one or more of the analogs of 7-hydroxyfrullanolide that can be used for preparing compositions comprise of frullanolides; 11a,13-dihydro-3a,7a- dihydroxy-4,5-epoxy-6p,7-eudesmanolide; 11a,1 3-dihydro-7a~acetoxy-3p-hydroxy-6p,7- eudesm-4-enolide; 3-keto-B-eudesmol; 11a,13-dihydro-3a,7a-dihydroxyeudesm-4-en- 60,12-olide; 11a,13-dihydro-3a,7a-dihydroxyfrullanolide; 11a,13-dihydro-7a,13-
dihydroxyfrullanolide; 11a,13-dihydro-7a-hydroxy-13-methaoxyfrullanolide; 20,70 dihydroxy-4-en-11,13-dihydroeudesm-6,12-olide; 2a-hydroxycostic acid; 3-keto-7a- hydroxyeudesm-4-en-6,12-olide (cryptomeridiol); 4-epicryptomeridiol; sphaeranthanolide; 2a-hydroxysphaerantholide; 2a-acetoxysphaerantholide; 2a,7a- dihydroxysphaerantholide; 2a-acetoxy-7a-hydroxysphaerantholide and 2a-acetoxy-5a- hydroxyisosphaerantholide.
The concentration of Sphaeranthus indicus derived 7-hydroxyfrullanolide or frullanolide/ eudesmanoid sesquiterpene compounds in the present invention individually or together varies in the range of 0.01% to 99.99%.
The composition wherein, the concentration of Garcinia mangostana fruit rind extract, a- mangostin and y-mangostin individually or jointly varies from 0.01% to 99.99%.
In another embodiment the herbal ingredient(s) or composition(s) of the present invention are useful to improve aerobic performance and capacity by influencing lactic acid metabolism and reducing fatigue as well as for alleviation of one or more of the biological energy markers including but not limited to ATP levels/production; Nitric
Oxide levels, NADH balance, leptin levels, adipocytes derived peptide
In another embodiment the herbal ingredient(s) can further be combined with one or more biological active ingredients comprising anti-diabetic, anti-hyperlipidemic, anti-obesity, anti-hypertensive, anti-platelet aggregation, anti-infective, anti-atherosclerotic, anti- inflammatory, anti-oxidant and bio-enhancing activity.
In a further exemplary embodiment, the composition may contain an effervescent. As is understood, an effervescent is an agent comprising one or more compounds which, act individually or together, evolve a gas on contact with water. The gas evolved is generally oxygen or, most commonly, carbon dioxide. Preferred effervescent agents comprise an acid component and a base component that react in the presence of water to generate carbon dioxide gas. The acid component can comprise one or more acids and the base component can comprise one or more bases. Preferably, the base component comprises an alkali metal or alkaline earth metal carbonate or bicarbonate and the acid component comprises an aliphatic carboxylic acid. Non-limiting examples of suitable bases for use in a base component include carbonate salts (e.g., calcium carbonate), bicarbonate salts (e.g., sodium bicarbonate), sesquicarbonate salts, and mixtures thereof. Sodium bicarbonate is a preferred base.
Non-limiting examples of suitable acids for use in-an acid component include citric acid, lactic acid, glutaric acid, phosphoric acid, acetic acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid, oxaloacetate, acid anhydrides of such acids, acid salts of such acids, and mixtures thereof. Citric acid is a preferred acid.
In a further exemplary embodiment, the composition may contain sweeteners. Preferred sweeteners for use in the present invention are sugars and sugar alcohols such as sucrose, fructose, dextrose, maltose, lactose, high fructose corn syrup solids, invert sugar, sugar alcohols, including sorbitol, as well as mixtures of these sugars and sugar alcohols. In order to deliver lower levels of solids per dosage, it may be preferred to use a higher intensity sweetener with the sugar or sugar alcohol. These higher intensity sweeteners include saccharin, cyclamates, acesulfame K, L-aspartyl-L-phenylalanine lower alkyl ester sweeteners (e.g., aspartame); L-aspartyl-D-alanine amides; L-aspartyl-D-serine amides; L-aspartyl-L-1-hydroxymethylalkaneamide sweeteners; L-aspartyl-1- hydroxyethyalkaneamide sweeteners; and L-aspartyl-D-phenylglycine ester and amide sweeteners. Further sweeteners contemplated for use with the compositions disclosed herein include sweeteners derived from stevia, sweeteners derived from momordica grosvenorii, and sweeteners derived from mogrosides. A particularly preferred sweetener system is a combination of sucralose with acesulfame K and corn syrup solids.
In another exemplary embodiment, the composition may be dissolved in water or in other liquids suitable for human consumption.
In another embodiment of the invention the various suitable solvents that can be used for preparing the extracts and fractions or extracting or fractionating the herbs such as
Sphaeranthus indicus, Garcinia mangostana include but not limited to C1-C5 alcohols, like ethanol, methanol; water and mixtures thereof; C1-C7 hydrocarbons such as hexane; esters like ethyl acetate and the like and mixtures thereof.
In another embodiment, the ingredients and compositions of the present invention may be formulated in dry form, liquid form, food product, dietary supplement or any suitable form such as tablet, a capsule or a soft chew.
In another embodiment the herbal ingredient(s) or composition(s) can be delivered in the form of controlled release tablets, using controlled release polymer-based coatings by the techniques including nanotechnology, microencapsulation, colloidal carrier systems and other drug delivery systems.
In another embodiment of the invention provides herbal ingredient(s) or their compositions nutritional/dietary supplements can be contemplated/made in the dosage form of healthy foods, or food for specified health uses such as solid food like chocolate or nutritional bars, semisolid food like cream or jam, or gel and also beverage and the like, such as refreshing beverage, lactic acid bacteria beverage, drop, candy, chewing gum, gummy candy, yoghurt, ice cream, pudding, soft adzuki bean jelly, jelly, cookie, tea, soft drink, juice, milk, coffee, cereal, snack bar and the like.
The flavorant(s) that may be included in the composition are not relevant to the inventive concepts disclosed herein, and those skilled in the art are familiar with the wide range of flavorants available. Therefore, any suitable flavorant or combination of flavorants, natural and/or artificial, is within the contemplated scope of the present disclosure.
In another exemplary embodiment, the composition may further include food colorants to improve the visual appearance of a drink prepared with the composition.
The flavoring agent or agents may provide a fruit flavor, cola flavor, vanilla flavor, or a chocolate flavor, by way of example and not by way of limitation. Sweeteners, natural or synthetic, such as sucrose, sucralose, aspartame, and/or acesulfame potassium, neotame, polydextrose, glycerin, sorbitol, and xylitol, may be used, by way of example and not by way of limitation. Coloring agents may be added. Agents such as citric acid, fumaric acid, adipic acid, tartaric acid, and in some instances lactic acid may be added to adjust for tartness.
Additional ingredients in the form of analgesics (e.g. aspirin), mild stimulants other than caffeine, which is mentioned above (e.g. green tea), or relaxants (e.g. melatonin), may be added in specialized product applications.
In other embodiment, the herbal ingredients and composition of this invention are useful in treating mitochondrial deficiencies in both humans and animals. It also can be used for enhancing or maintaining physical or mental performance, reducing infection in physically stressed athletes or non-athletes from intense physical exercises. Moreover, it can be an activator of Sirtuin.
In another exemplary embodiment the biologically acceptable ingredients or compositions can further be combined with one or more pharmaceutically or dietetically acceptable excipients, carriers and diluents, comprising glucose, fructose, sucrose, maltose, yellow dextrin, white dextrin, aerosil, microcrystalline cellulose, calcium stearate, magnesium stearate, sorbitol, stevioside, corn syrup, lactose, citric acid, tartaric acid, malic acid, succinic acid, lactic acid, L-ascorbic acid, dl-alpha-tocopherol, glycerin, propylene glycol, glycerin fatty ester, poly glycerin fatty ester, sucrose fatty ester, sorbitan fatty ester, propylene glycol fatty ester, acacia, carrageenan, casein, gelatin, pectin, agar, vitamin B group, nicotinamide, calcium pantothenate, amino acids, calcium salts, pigments, flavors, preservatives, distilled water, saline, aqueous glucose solution, alcohol, propylene glycol and polyethylene glycol, various animal and vegetable oils, white soft paraffin, paraffin and wax.
In still another embodiment, the invention features a method for enhancing physical or mental performance, steady maintenance of energy, physical endurance and mental alertness in humans and animals, wherein the method comprises administering to a subject in need thereof an effective amount of at least one herbal ingredient selected from the extract(s), fraction(s), compound(s), extracts or fractions standardized to active compound(s)/7-hydroxyfrullanolide derived from Sphaeranthus indicus and compositions thereof. Examples of improved physical performance include increased stamina and improved speed, strength, power, endurance, flexibility, agility, balance, focus coordination, reaction time, fatigue recovery and also increase of sex stamina. Examples of improved mental performance include improved sharpness, attention span, mental alertness, cognitive functions, mood elevation, and recovery or reduction of mental fatigue (e.g., following a high-intensity physical exercise). By properly administrating the ingredient or composition, a subject's physical or mental performance can be greatly enhanced without deleterious side effects.
In still another embodiment, the invention features use of at least one herbal ingredient selected from the extract(s), fraction(s), compound(s), extracts or fractions standardized to active compound(s)/7-hydroxyfrullanolide derived from Sphaeranthus indicus and compositions thereof to enhance physical activity, physical fitness, mental alertness, enhancing energy levels, stamina levels, circulatory health, blood vessel health and for better mental health in warm blooded animal or humans or animals.
In still another embodiment of the invention, use of at least one herbal ingredient selected from the extract(s), fraction(s), compound(s), extracts and fractions standardized to active compound(s)/7-hydroxyfrullanolide derived from Sphaeranthus indicus and compositions thereof for the preparation of a medicament useful for enhancing physical or mental performance, steady maintenance of energy, physical endurance and mental alertness in humans and animals.
Those of ordinary skill in the art will appreciate that changes could be made to the embodiments described above without departing from the broad inventive concept thereof, It is understood, therefore, that this invention is not limited to the particular embodiments or examples disclosed, but is intended to cover modifications within the objectives and scope of the present invention as defined in the specification.
Example 1
Sphaeranthus indicus methanol extract (LI112500); Sphaeranthus indicus flower heads (1 kg) were taken in a round bottom flask and extracted with methanol (8 L) at 60 - 65°C temperature for 2 h. The extract was filtered and the spent raw material was re-extracted twice with methanol (2 x 6 L) under similar conditions. The combined extract was fine filtered and concentrated over a climbing film evaporator to obtain a residue (110 g). The methanol extract (L112500) showed 11% of 7-hydroxyfrullanolide by HPLC method of analysis.
Sphaeranthus indicus methanol extract standardized to 5% 7-hydroxyfrullanolide
Sphaeranthus indicus methanol extract containing 7-hydroxyfrullanolide as obtained above was diluted with microcrystalline cellulose and magnesium strearate along with 2% by weight of aerosil to obtain Sphaeranthus indicus powdered methanol extract standardized to 5% 7-hydroxyfrullanolide (L112508).
Example 2
Sphaeranthus indicus ethanol extract: Sphaeranthus indicus flower heads (1 kg) were : taken in a RB flask and extracted with ethanol (8 L) at 60- 65°C temperature for 2 h. The extract was filtered and the spent raw material was re-extracted twice with ethanol (2 x 6
L) under similar conditions. The combined extract was fine filtered and concentrated over a climbing film evaporator to obtain a residue (98 g). The ethanol extract showed 12% of 7-hydroxyfrullanolide by HPLC method of analysis.
Example 3
Garcinia mangostana rind methanol extract (LI80013): Shade dried fruit rind (1Kg) of
Garcinia mangostana was pulverized to coarse powder, and extracted with 90% methanol (5L) for 2 hrs at 60-65 C. The solvent was separated from the raw material by filtration.
Extraction process was repeated three times using 90% methanol (2x3 L & 1x2 L). The combined extracts were fine filtered and concentrated under reduced pressure and allowed to precipitate at ambient temperature. The solid separated was filtered to give a dry powder (150 g, a-mangostin: 21% and y-mangostin: 2.5%).
Example 4
Garcinia mangostana methanol extract standardized to 10% o-mangostin:
Garcinia mangostana methanol extract containing a-mangostin as obtained above (example 3) was diluted with microcrystalline cellulose and magnesium strearate along with 2% aerosil to obtain Garcinia mangostana methanol extract standardized to 10% a- mangostin (LI180018).
Example 5
Garcinia_mangostana rind ethanol extract: Shade dried fruit rind (1Kg) of Garcinia mangostana was pulverized to coarse powder, and extracted with 90% ethanol (SL) for 2 hrs at 60-65 C. The solvent was separated from the raw material by filtration. Extraction process was repeated thrice using 90% ethanol (2x3 L & 1x2 L). The combined extracts were fine filtered and concentrated under reduced pressure and allowed to precipitate at ambient temperature. The solid separated was filtered to give ethanol extract as a dry powder (136 g, a-Mangostin: 22%).
Example 6
Composition LI12506F: The composition LI12506F was prepared by combining the methanol extract of Sphaeranthus indicus (L112500) and 90% methanol extract of
Garcinia mangostana (LI80013), both as prepared above, in the ratio of 3:1.
Example 7
Formulation LI12507F (Merastin®): The Sphaeranthus indicus powder extract standardized to minimum 5% 7-hydroxyfrullanolide (LI12508) and Garcinia mangostana methanol extract standardized to 10% a-mangostin (LI80018) as prepared above were combined at 3 : 1 ratio and properly blended to obtain LI12507F.
Example 8 :
Composition LI12517F:
Composition LI12517F was prepared by mixing unit doses of the following components:
One part of Sphaeranthus indicus ethanol extract (1 g) and
Three parts of Garcinia mangostana 90% ethanol extract (3 g).
Example 9
A study was conducted using Sphaeranthus indicus extract standardized to 5% 7- hydroxyfrullanolide (L112508) and a composition containing Sphaeranthus indicus extract standardized to 5% 7-hydroxyfrullanolide in combination with Garcinia mangostana extract standardized to 10% a-mangostin (LI12507F) to assess their efficacy as an anti-obese supplement in a double blind placebo controlled study in obese human subjects. Sixty obese subjects (27.6 % male; 72.4 % female; ages 22-50 years) were included in a randomized, double-blind, placebo-controlled study of 56 days duration.
The participants (BMI 30 to 40) were randomized into three groups; placebo, LI12508 group and LI12507F group. The participants received either 600 mg/day of LI112508 and 800 mg of LI12507F formulation in two divided doses or two identical placebo capsules and all of them remained on a calorie-controlled diet (2000 Calories/day) and 30 min walking for 8 weeks. Various parameters including, physical, anthropomorphic, biochemical and questionnaire based evaluation including quality of life have been studied. The S. indicus extract (LI12508) and its formulation LI12507F provided significant reduction in body weight in both the treatment groups and also indicated promise for their potential use in controlling serum triglyceride levels.
Impact of Weight on Quality of Life Questionnaire-Lite Version (IWQOL-Lite) including subjects feedback was administered to all the subjects at each evaluation point including days 0, 14, 28 and 56 was assessed. Subjects expressed improvement in various parameters including increased mobility, increased walking speed, increased walking distance and time, feeling untired, feeling light and active. Number of subjects expressed such improvement in physical ability and endurance was more in supplement groups compared to placebo group.
Both LI12508 and LI12507F also showed unexpectedly improved quality of life and improved energy, exercise ability and endurance in subjects supplemented with the treatments when compared the placebo treated group. This includes increased mobility, increased walking speed, increased walking distance, lack of fatigue, feeling untired, feeling light and active.
Example 10
Intracellular ATP level in the cells treated cells with L112508 and LI12507F were measured by luminescence based ATP detection assay system, ATPlite (PerkinElmer
Inc., Waltham, MA). Briefly, equal number of L6 Rat myocytes was plated in each well of a 96-well cell culture plate and cultured in DMEM supplemented with 10% FBS. The cells were treated with different concentrations of test samples (LI12508 and LI12507F) for 4h and thereafter, to each well 50 ul of cell lysis buffer were added. The vehicle control culture wells received 0.2% DMSO (v/v). Finally, 50 ul of substrate solution was added to each well and incubated at room temperature for 5 min on plate shaker. After 10 minutes of dark adaptation, the luminescence was read in a luminometer (Modulus
Multimode Reader, Turner Biosystems Inc., Sunnyvale, CA). A serial dilution of an ATP standard solution ranging from 1x10° M to blank was applied to the assay plate.
Intracellular ATP level was quantitatively estimated from a standard curve plotted with luminescence units vs. known concentrations of ATP.
Table 1 pg/mL | Concentration
CT eww em
Example 11:
Evaluation of Energy Endurance Capacity of herbal extract in Swiss albino mice:
Eighteen Swiss albino mice of 20 weeks old were selected and examined for health status and acclimatized for one week before initiation of the study. The animals were randomly divided into three groups each consisting of 6 animals (3 males and 3 females) corresponding to two doses (100 and 250mg/kg body weight) of test substance LI12508 and vehicle control. The animals were treated orally with allocated test substances or vehicle daily for 1 week. Swimming exercise (15 min) was initiated after 1 hr of treatment and continued daily for 7 days. Mice were allowed to swim with supporting constant loads (lead fish sinkers, attached to the tail) corresponding to 10% of their body weight, in a acrylic tank filled with water. On day 7" this swimming exercise for 15 min was tracked using the SMART video tracking system (Panlab S.L.U). Swimming time or resting time, Distance travelled and velocity of swimming was measured using the tracking software. Resting time and its percentage, moving slow and its percentage, moving fast and its percentage, total path length of swimming and average velocity were analyzed using SMART video tracking software and the data is summarized in table 2.
There was a significant decrease in mean resting time and a significant increase in mean slow swimming time, mean fast swimming time and average distance covered in both 100 mg/kg and 250 mg/kg of LI12508 treated group animals when compared to control treated animal group as summarized in the figures 1 to 2. Moreover, animals treated with
250 mg/kg p.o showed a significant increase in average velocity as compared to control group as depicted in figure 4.
Table 2
Energy Endurance Potential of LI12508 on Forced Swimming Test Parameters
Paramete Restin | Movin Movin Avera
Resting Movin Movin
Is Distance g g Slow g Fast ge
Time g Slow g Fast
Test (cm) Time | Time Time Velocit (Sec) (“) (%)
Article (%) (Sec) (Sec) y 39588.39 | 662.63 | 73.57 | 192.74 | 21.40 | 45.29 111.40
CMC : 503% + + + + + + + (Control) 1.44 5247.84 36.94 4.10 25.99 2.89 | 12.96 6.72
LI12508 | 48345.11 64.83 27.87 116.27 574.63* 245.57* 7.30 + 100 *x + + 64.09% + g/k + * 2.90 * 2.33 | £5.36 OT om m . . +35. . s 31.56 19.48 2549.01 57160.52 125.96
LI112508 565.71* | 62.80 |252.40* | 28.02 | 82.71* ** 9.18 + * 250 * + * + * g/k * 2.75 + 1.65 142 * m + . . + 8 4810.60 6.39 24.78 14.82 12.83
Values are expressed as Mean + S.E.M, n=6. * p<0.03, **p<0.01 as compared to CMC control (ANOVA followed by Tukey’s Test)
Claims (14)
1. A Sphaeranthus indicus derived herbal ingredient selected from the extracts and fractions standardized to at least one frullanolide/eudesmanoid sesquiterpene compound as a natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof.
2. A composition comprising at least one Sphaeranthus indicus derived herbal ingredient selected from the extracts and fractions standardized to at least one frullanolide/eudesmanoid sesquiterpene compound in combination with at least one biologically active ingredient selected from extract of Garcinia mangostana fruit rind, Osmium basilicum, Zingiber officinalis, Tribulus terrestris, vitamins, amino acids, taurine, an extract of Ginkgo biloba, Rhodiola and an extract of guarana, optionally containing an excipient, diluent or carrier as a natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof.
3. A composition comprising at least one Sphaeranthus indicus derived herbal ingredient selected from the extract and fraction standardized to at least one frullanolide/eudesmanoid sesquiterpene compound in combination with an extract of Garcinia mangostana fruit rind standardized to a-mangostin or y-mangostin or both and at least one excipient/diluent as a natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof.
4. The Sphaeranthus indicus derived ingredient according to claims 1 to 3, wherein the compound for standardization is selected from the group consisting of 7- hydroxyfrullanolide; 110,13-dihydro-3a,7a-dihydroxy-4,5-epoxy-68,7- eudesmanolide; 11a,13-dihydro-7a-acetoxy-3p-hydroxy-6f,7-eudesm-4-enolide; 3-keto--eudesmol; 11a,13-dihydro-3a,7a-dihydroxyeudesm-4-en-6a,12-olide; 110,13-dihydro-3a,7a-dihydroxyfrullanolide; 11a,13-dihydro-7a,13- dihydroxyfrullanolide; 110,13-dihydro-7a-hydroxy-13-methaoxyfrullanolide;
2a, 70-dihydroxy-4-en-11,13-dihydroeudesm-6,12-olide; 2a-hydroxycostic acid; 3-keto-7a-hydroxyeudesm-4-en-6,12-olide (cryptomeridiol); 4-epicryptomeridiol; sphaeranthanolide; ~~ 2o-hydroxysphaerantholide; 2a-acetoxysphaerantholide; 2a,7a-dihydroxysphaerantholide; 2a-acetoxy-7a-hydroxysphaerantholide and 2a- acetoxy-5Sa-hydroxyisosphaerantholide or mixtures thereof.
5. The Sphaeranthus indicus derived ingredient as claimed in claims 1 and 2, is obtained from at least one of the plant part selected from leaves, flower heads, stem, root, whole plant or mixtures thereof or is chemically synthesized.
6. The herbal extracts and fractions as claimed in claims 1 to 3, wherein the solvent for extracting or fractionating is selected from the group consisting of C1 to C5 alcohols; C1 to C7 hydrocarbons; esters; water and mixtures thereof.
7. The Sphaeranthus indicus extracts or fractions standardized to atleast one frullanolide/eudesmanoid sesquiterpene compound as claimed in claims 1 and 2, wherein the concentration of active compound 7-hydroxyfrullanolide/other frullanolide/eudesmanoid sesquiterpene(s) in the extract(s) and fraction(s) derived from Sphaeranthus indicus either individually or together varies in the range of
0.01% to 99.99%.
8. The compositions as claimed in claims 2 and 3, wherein the concentration of active compounds, a-mangostin and y-mangostin, either individually or jointly in Garcinia mangostana derived extract(s) or fraction(s) varies from 0.01% to
99.99%.
9. The herbal ingredient or composition as claimed in claims 1 to 3, wherein said ingredient or composition formulated into a dietary supplement, food ingredient, beverage, snack or energy drink.
10. The herbal ingredient derived from Sphaeranthus indicus standardized to 7- hydroxyfrullanolide according to claim 1, for enhancing physical activity, physical fitness, mental alertness, enhancing energy levels, stamina levels,
circulatory health, blood vessel health and for better mental health in warm blooded animal.
11. The composition according to claim 2, for enhancing physical activity, physical fitness, mental alertness, enhancing energy levels, stamina levels, circulatory health, blood vessel health and for better mental health in warm blooded animal.
12. A method of enhancing natural energy to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof, wherein the method comprises administering to a subject or mammal or warm blooded animal a therapeutically effective quantity of at least one Sphaeranthus indicus derived herbal ingredient selected from the extracts and fractions standardized to at least one frullanolide/eudesmanoid sesquiterpene compound as claimed in claim 1.
13. A method of enhancing natural energy to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof, wherein the method comprises administering to a subject or mammal or warm blooded animal a therapeutically effective quantity of a composition as claimed in claim 2.
14. A method of enhancing natural energy to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof, wherein the method comprises administering to a subject or mammal or warm blooded animal a therapeutically effective quantity of a composition as claimed in claim 3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2296CH2010 | 2010-09-11 | ||
PCT/IN2011/000612 WO2012032544A2 (en) | 2010-09-11 | 2011-09-07 | Sphaeranthus indicus derived ingredients and their compositions for enhacing physical performance and energy levels |
Publications (1)
Publication Number | Publication Date |
---|---|
SG188424A1 true SG188424A1 (en) | 2013-04-30 |
Family
ID=45811029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013016597A SG188424A1 (en) | 2010-09-11 | 2011-09-07 | Ingredients derived from sphaeranthus indicus |
Country Status (7)
Country | Link |
---|---|
KR (1) | KR20130119424A (en) |
CN (1) | CN103108556A (en) |
AU (1) | AU2011300376B2 (en) |
CA (1) | CA2810793C (en) |
MY (1) | MY166221A (en) |
SG (1) | SG188424A1 (en) |
WO (1) | WO2012032544A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2896990A1 (en) * | 2013-01-03 | 2014-07-10 | Laila Nutraceuticals | Synergistic dietary supplement compositions for enhancing physical performance and energy levels |
US9872871B2 (en) | 2013-04-23 | 2018-01-23 | Aarhus Universitet | Compositions for use in restoring muscle glycogen and/or muscle mass |
CA3023426A1 (en) * | 2016-05-21 | 2017-11-30 | Laila Impex | Dietary supplements and compositions for enhancing physical performance and energy levels |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002047125A (en) * | 2000-05-26 | 2002-02-12 | Shiseido Co Ltd | Skin care preparation for inhibiting sebum secretion |
US20070196298A1 (en) * | 2005-05-31 | 2007-08-23 | Kostick Richard H | Cosmetic and dermatological formulations with natural pigments and methods of use |
EA014070B1 (en) * | 2005-09-30 | 2010-08-30 | Пирамал Лайф Сайнсиз Лимитед | Use of a herbal composition for the treatment of inflammatory disorders |
AU2010220058B2 (en) * | 2009-02-02 | 2016-02-18 | Laila Nutraceuticals | Composition from Sphaeranthus indicus and Garcinia mangostana for the control of metabolic syndrome |
-
2011
- 2011-09-07 CN CN2011800435489A patent/CN103108556A/en active Pending
- 2011-09-07 MY MYPI2013700389A patent/MY166221A/en unknown
- 2011-09-07 CA CA2810793A patent/CA2810793C/en active Active
- 2011-09-07 KR KR1020137009108A patent/KR20130119424A/en not_active Application Discontinuation
- 2011-09-07 SG SG2013016597A patent/SG188424A1/en unknown
- 2011-09-07 AU AU2011300376A patent/AU2011300376B2/en not_active Ceased
- 2011-09-07 WO PCT/IN2011/000612 patent/WO2012032544A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
MY166221A (en) | 2018-06-22 |
WO2012032544A2 (en) | 2012-03-15 |
KR20130119424A (en) | 2013-10-31 |
CA2810793C (en) | 2023-10-31 |
CA2810793A1 (en) | 2012-03-15 |
AU2011300376A1 (en) | 2013-04-04 |
AU2011300376B2 (en) | 2015-12-03 |
WO2012032544A3 (en) | 2012-05-10 |
CN103108556A (en) | 2013-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019200802B2 (en) | Synergistic dietary supplement compositions for enhancing physical performance | |
US20050276839A1 (en) | Appetite satiation and hydration beverage | |
WO2008004340A1 (en) | Senescence inhibitor | |
TW200816992A (en) | Quercetin-containing compositions | |
TW200913988A (en) | Anti-fatigue agent and oral composition each comprising andrographolide as active ingredient | |
EP2859896A1 (en) | Pharmaceutical compositions for the treatment of muscular disorders | |
WO2007066642A1 (en) | Oral preparation for preventing or improving skin dryness | |
JP2019019142A (en) | Inhibitors of vcam-1 expression | |
KR20240004452A (en) | 1-Methylxanthine-based bioactive compositions and methods of using the same | |
AU2011300376B2 (en) | Ingredients derived from Sphaeranthus indicus | |
US20150050260A1 (en) | Pyrroloquinoline quinone based compositions and uses | |
US10105347B2 (en) | Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels | |
US10542989B2 (en) | Synergistic dietary supplement compositions for enhancing physical performance and energy levels | |
JP5048258B2 (en) | Rebound inhibitor | |
JP2009533433A (en) | Compositions containing pyruvate alkyl esters and uses thereof | |
JP2009023948A (en) | Dopamine-inhibiting agent | |
CN117979971A (en) | Bioactive compositions based on 1-methylxanthines and methods of use thereof | |
JP2024015087A (en) | Oral composition |